Clinical Evidence: What the Data Shows Phase 3 Trial Results (Zepbound Studies) The REFRAME and related trials demonstrated: Weight Loss Average: 22.5% body weight reduction at 68 weeks Range: 18-28% depending on population Significantly exceeds tirzepatide (21% at comparable doses) Body Composition Preferential loss of visceral fat (the dangerous kind) Better preservation of lean muscle vs
Wegovy (semaglutide) Injector 1.7 mg/0.75 mL, 4 Pens Per Box is a medication used for chronic weight management in adults with obesity or excess weight who have at least one weight-related health condition, such as high blood pressure, type 2 diabetes, or high cholesterol. It is used in combination with a reduced calorie diet and increased physical activity. Wegovy is a glucagon-like peptide-1 (GLP-1) receptor antagonist and works by slowing down digestion, decreasing appetite, and increasing feelings of fullness, which helps with weight loss. It is administered as a subcutaneous injection and comes in a package of 4 pens for 4 weeks of treatment
However, we also offer at-home injection training so you can administer shots on your own if preferred
Dosage recommendations can vary based on individual needs and health goals
That doesnt mean its wrong the chemistry is reasonable but it does mean the 100x more potent claims you see in promotional copy are essentially marketing language layered on top of plausible but unverified pharmacokinetic logic
